Mobile

A study looking at the immune response in chronic hepatitis C patients treated with Sofosbuvir and Daclatasvir combination with or without Ribavirin for 12 or 24 weeks

Update Il y a 5 ans
Reference: EUCTR2014-002808-25

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective for this study is to analyse the impact of inhibition of viral replication by interferon-free therapy consisting of Sofosbuvir and Daclatasvir (±Ribavirin) on the phenotype and function of the innate immune cells and HCV-specific T-cells, in treatment-naive or previously relapsed chronic hepatitis C patients with GT-1, -3 or -4 infection.

Inclusion criteria

  • Chronic hepatitis C

Links